Intermediate-term clinical experience with the Ahmed Glaucoma Valve implant - 08/09/11
, Anne L Coleman, MD, PhD b, Scott W Siegner, MD b, Marlene R Moster, MD c, Richard A Hill, MD dAbstract |
PURPOSE: We studied the intermediate-term clinical experience with the Ahmed Glaucoma Valve implant (New World Medical, Inc, Rancho Cucamonga, California).
METHODS: In this multicenter, retrospective case series, we studied 159 eyes (144 patients) treated with the Ahmed Glaucoma Valve with a mean ± SEM (standard error of mean) follow-up of 13.4 ± 0.7 months (range, 4 to 44 months). The mean ± SEM age was 60.9 ± 1.9 years (range, 0.1 to 103 years). Surgical success was defined as intraocular pressure less than 22 mm Hg and greater than 5 mm Hg without additional glaucoma surgery and without loss of light perception. Postoperative use of antiglaucoma medications was not a criterion for success or failure. The definition of hypotony was intraocular pressure of 5 mm Hg or less in two consecutive visits.
RESULTS: Intraocular pressure was reduced from a mean of 32.7 ± 0.8 mm Hg before surgery to 15.9 ± 0.6 mm Hg (P < .0001) at the most recent follow-up after surgery. The number of antiglaucoma medications was decreased from 2.7 ± 0.1 before surgery to 1.1 ± 0.1 after surgery (P < .0001). The cumulative probability of success was 87% at 1 year and 75% at 2 years after surgery (Kaplan-Meier life-table analysis). Postopera-tively, 24 (15%) of 159 eyes had intraocular pressure greater than or equal to 22 mm Hg. The visual acuity was improved or within one Snellen line in 131 eyes (82%). Complications occurred in 75 eyes (47%), the majority of which did not affect surgical outcome. The most common complication was obstruction of the tube, which was observed in 17 eyes (11%). Transient postoperative hypotony was found in 13 eyes (8%).
CONCLUSIONS: The Ahmed Glaucoma Valve implant is effective in lowering intraocular pressure, and postoperative hypotony is not commonly associated with this implant.2
Le texte complet de cet article est disponible en PDF.Plan
 | Supported in part by Research to Prevent Blindness, Inc, New York, New York. |
Vol 127 - N° 1
P. 27-33 - janvier 1999 Retour au numéro
Article précédent
- Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients
- L.Jay Katz, the Brimonidine Study Group∗The Brimonidine Study Group members are listed at the end of the article. ∗
- The Ahmed Valve in refractory pediatric glaucoma
- Judith A Englert, Sharon F Freedman, Terry A Cox
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?